Journal
NANO LETTERS
Volume 23, Issue 18, Pages 8674-8682Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.nanolett.3c02514
Keywords
molecularly imprinted polymers; VEGF; nanomedicine; anti-angiogenesis; cancer treatment
Ask authors/readers for more resources
This study reports the rational engineering of VEGF-targeted molecularly imprinted polymer nanoparticles for anti-angiogenic cancer therapy. These nanoparticles can effectively block the signaling of vascular endothelial growth factor and demonstrate anti-angiogenic effects in vivo.
The VEGF-VEGFR2 (VEGF = vascular endothelial growth factor) signaling has been a promising target in cancer therapy. However, because conventional anti-angiogenic therapeutics suffer from drawbacks, particularly severe side effects, novel anti-angiogenic strategies are much needed. Herein, we report the rational engineering of VEGF-targeted molecularly imprinted polymer nanoparticles (nanoMIP) for anti-angiogenic cancer therapy. The anti-VEGF nanomedicine was prepared via a state-of-the-art molecular imprinting approach using the N-terminal epitope of VEGF as the template. The nanoMIP could target the two major pro-angiogenic isoforms (VEGF165 and VEGF121) with high affinity and thereby effectively block the VEGF-VEGFR2 signaling, yielding a potent anti-angiogenic effect of killing two birds with one stone. In vivo experiments demonstrated that the anti-VEGF nanoMIP effectively suppressed tumor growth via anti-angiogenesis in a xenograft model of human colon carcinoma without apparent side effects. Thus, this study not only proposes an unprecedented anti-angiogenic strategy for cancer therapy but also provides a new paradigm for the rational development of MIPs-based drug-free nanomedicines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available